Unique RNA-based approach for the treatment of heart diseases
11 May 2017, Munich – Cardior Pharmaceuticals has completed a EUR 15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High-Tech…
Join Europe’s leading showcase for life-science inventions!
Ascenion is proud to present a strong line-up of speakers, participants and technologies for this year’s BioVaria Anniversary Edition to be held on 22 and 23 May 2017 in Munich.
Discover an unmatched density of commercially attractive licensing opportunities emanating from leading…
Network with your peers, seasoned entrepreneurs and industry experts to gain valuable feedback on how to improve your project’s chances of success in a casual and fun environment.
Whether you are a company with a pipeline of preclinical assets, a nascent start-up or a researcher working on the next innovation on the verge of spinning out, this…
The role of knowledge and technology transfer has developed considerably over the past few years. A contribution by Christian Stein in the recently published Ernst & Young German Biotechnology Report "Spot on Innovation" highlights the development of technology transfer in Germany and shows the importance of knowledge and technology transfer…
At the end of last year, Christian Stein was elected to the Board of Directors of TechnologieAllianz, the German Association for knowledge and technology transfer, and is now responsible for international cooperation and events.
Focusing on promoting the development and dissemination of professional standards for technology transfer,…
Technology Sneak Peek from Ascenion: Human T-cell receptors for cancer therapy
4 April 2017, Munich, Germany – On 22-23 May 2017, dealmakers from biotech, pharma and finance will come together in Munich for the 10th BioVaria to learn about breakthrough academic inventions and emerging life-science trends, and to initiate partnerships with…
Join over 400 fellow leaders in medical innovation to be part of the discussion to shape and address the biggest challenges and opportunities in healthcare today! During two conference days, you will get the opportunity to connect with entrepreneurs, scientists, physicians, investors, policymakers, and industry leaders from Germany, Europe,…
A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach to develop a novel hybrid endoscopic instrument for the diagnosis of oesophageal cancer (OC). The new device will combine two groundbreaking technologies — multi-spectral optoacoustic…
OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the first closing of a Series B financing round with EUR 8.3 million. The funding comes from OMEICOS’ existing investor consortium, which also includes Ascenion.
In addition, the company has enrolled the first subject…
The transition to a clinical company is probably the most adventurous and riskiest step in the life of a biotech company. Get it right the first time! In a casual and relaxed environment, (to-be) founders can learn from seasoned entrepreneurs and industry experts, make valuable contacts and gain insights into how to improve their project’s chances…
At the end of January, the German Federal Institute for Drugs and Medical Devices (BfArM) and the Federal Ministry of Health (BMG) announced the launch of an Innovation Office. It will be a first port of call for scientists and small companies wishing to develop innovative medical products and who have hitherto had little experience of regulatory…
This January, the UTILE project was launched under the European H2020 Research and Innovation Program. It is designed to help commercialize the results from EU-funded health-related research projects by creating an online market place that brings together ‘innovation providers’ and ‘innovation developers’. Coordinated by PNO consultants, 11…
Heidelberg Pharma, a subsidiary of Wilex AG, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have signed a license agreement on a set of anti-BCMA antibodies generated at the MDC. The deal follows an option agreement between the partners mediated by Ascenion last September.
Based on the MDC antibodies…
This year’s BioVaria Anniversary Edition will, for the first time, extend over two days and include the promising field of digital health. Top-tier academic institutions and universities from all over Europe will present their most attractive partnering and investment opportunities in the life-science field – each one selected for BioVaria in a…
LentiBOOSTTM, an innovative gene therapy adjuvant, has got the green light from the FDA for use in a Phase III clinical trial. The technology, which was jointly developed by SIRION Biotech and the Helmholtz Zemtrum München, can increase the transduction efficacy of lentiviral vectors in human cells by up to 90 percent. Remarkably, this even works…
EUR 9 million Series A financing was secured by HepaRegeniX at the end of 2016 – sufficient to further advance its innovative approach to the treatment of liver disease. The first milestone is the development of a lead candidate, the second the preparation of clinical trials. The concept is based on research results previously obtained by…
Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and…
We’d like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive collaboration over the past year. Instead of sending Christmas cards, we have decided to support EinDollarBrille e.V. with a donation. The organization aims to help 150 million people around the world by…
amcure, a company that received support from Ascenion’s Spinnovator coaching program from the beginning, reports a significant milestone: At the end of October the company initiated a Phase I/Ib study with its lead programme AMC303 in cancer patients. The first patient has already been treated. The study is designed to assess the safety,…
Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I study comprises two parts involving healthy volunteers and elderly, autoantibody-positive individuals who are otherwise also healthy. The goal is to evaluate the candidate’s safety, tolerability,…
